Disease Management and Health Outcomes

, Volume 10, Issue 1, pp 41–54 | Cite as

Management of Alzheimer’s Disease

Defining the Role of Donepezil
Drugs In Disease Management


Alzheimer’s disease affects 15 million people worldwide. As the elderly population grows, the incidence of Alzheimer’s disease will also increase. It is estimated that by 2010, 40 million US citizens will be over the age of 65 years and by 2040, it is predicted that 14 million US citizens will have Alzheimer’s disease. There is currently no treatment which stops or delays the progression of this condition; however, anticholinesterase therapy provides some symptomatic relief. The cognitive impairment experienced by patients with Alzheimer’s disease is partially due to degeneration of cholinergic pathways within the CNS and therefore symptomatic treatments have focused on restoring cholinergic inputs.

Donepezil is a second generation anticholinesterase drug which reduces cortical acetylcholinesterase activity and improves, or at least slows the decline in, cognitive functioning in patients with Alzheimer’s disease. In patients with mild to moderate Alzheimer’s disease, treatment with donepezil (5 to 10 mg/day) for 1 year extended the median time to a clinically evident functional decline by 5 months compared with treatment with placebo. In addition, patients receiving donepezil have also shown significant improvement in ratings of global function, cognition, activities of daily living and disease severity over a 1-year period (p < 0.05 in each case). In patients with moderate to severe Alzheimer’s disease, donepezil significantly improved ratings of behavior compared with placebo (p < 0.05).

Donepezil treatment is associated with the well recognized adverse events which accompany cholinergic therapy. The most frequently reported adverse events with donepezil treatment are gastrointestinal complaints such as nausea, diarrhea and vomiting, and CNS conditions including dizziness, headache and insomnia. These adverse events are typically mild and transient. Preliminary data from a direct comparison of donepezil and rivastigmine suggests that donepezil may exhibit an improved tolerability profile compared with rivastigmine.

Recent data suggest that use of donepezil is associated with a significant delay in the time to institutionalization. Data from modeling and pharmacoeconomic studies also predict that use of donepezil may lead to a reduction in costs. However, it is likely that these savings will be distributed across multiple healthcare and non-healthcare systems and may not be fully represented in the budgets of those who are responsible for the direct costs of providing this medication.

Donepezil is the only cholinesterase inhibitor currently available in a once daily formulation and with a relatively simple dose escalation schedule. This regimen coupled with a good tolerability profile makes donepezil a first-line treatment for patients with mild to moderate Alzheimer’s disease. However, only direct comparisons between donepezil and other second generation anticholinesterases will provide definitive data which can be used to maximize patient outcomes. In addition, wider clinical experience with donepezil may help to identify a subgroup of patients who respond strongly to treatment thus improving patient care and reducing costs.


  1. 1.
    Dooley M, Lamb HM. Donepezil: a review of its use in Alzheimer’s disease. Drugs Aging 2000 Mar; 16 (3): 199–226.PubMedCrossRefGoogle Scholar
  2. 2.
    National Institute for Clinical Excellence. NICE issues guidance on drugs for Alzheimer’s disease. Media Rel 2001 Jan 19: 4.Google Scholar
  3. 3.
    Blass JP. Pathophysiology of Alzheimer’s syndrome. Neurology 1993; 43 (Suppl. 4): 25–38.Google Scholar
  4. 4.
    Evans DA, Beckett LA, Field TS, et al. Apolipoprotein E episolon-4 and incidence of Alzheimer disease in a community population of older persons. JAMA 1997 Mar 12; 277: 822–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Cacabelos R, Alvarez A, Lombardi V, et al. Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics. Drugs Today 2000 Jul; 36: 415–99.Google Scholar
  6. 6.
    Post SG, Whitehouse PJ, Binstock RH, et al. The clinical introduction of genetic testing for Alzheimer disease: an ethical perspective. JAMA 1997 Mar 12; 277: 832–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000 Jan; 157: 4–15.Google Scholar
  8. 8.
    Fisher A, Michaelson DM, Brandeis R, et al. Ml muscarinic agonists as potential disease-modifying agents in Alzheimer’s disease. Rationale and perspectives. Ann N Y Acad Sci 2000; 920: 315–20.PubMedCrossRefGoogle Scholar
  9. 9.
    Mayeux R, Sano M. New treatment options in Alzheimer’s disease reviewed. N Engl J Med 1999 Nov 25; 341: 1670–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Cummings JL, Jeste DV. Alzheimer’s disease and its management in the year 2010. Psychiatr Serv 1999 Sep 9; 50: 1173–7.PubMedGoogle Scholar
  11. 11.
    Fillit HM. The pharmacoeconomics of Alzheimer’s disease. Am J Manag Care 2000 Dec; 6 (22 Suppl): 1139–48.Google Scholar
  12. 12.
    Guttman R, Altman RD, Nielsen NH. Alzheimer disease. Report of the Council on Scientific Affairs. Arch Fam Med 1999 Jul-1999 31; 8 (4): 347–53.PubMedCrossRefGoogle Scholar
  13. 13.
    Mortimer JA, Graves AB. Education and other socioeconomic determinants of dementia and Alzheimers disease. Neurology 1993; 43 (Suppl. 4): 39–44.Google Scholar
  14. 14.
    Yamada M, Sasaki H, Mimori Y, et al. Prevalence and risks of dementia in the Japanese population: RERF’s Adult Health Study Hiroshima subjects. J Am Geriatr Soc 1999 Feb; 47: 189–95.Google Scholar
  15. 15.
    Kawas C, Gray S, Brookmeyer R, et al. Age-specific incidence rates of Alzheimer’s disease: the Baltimore Longitudinal Study of Aging. Neurology 2000 Jun 13; 54 (11): 2072–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Liu HC, Fuh JL, Wang SJ, et al. Prevalence and subtypes of dementia in a rural Chinese population. Alzheimer Dis Assoc Disord 1998 Sep; 12: 127–34.Google Scholar
  17. 17.
    Fratiglioni L, Viitanen M, von Strauss E, et al. Very old women at highest risk of dementia and Alzheimer’s disease: incidence data from the Kungsholmen Project, Stockholm. Neurology 1997 Jan; 48: 132–8.Google Scholar
  18. 18.
    Evans DA, Hebert LE, Beckett LA, et al. Education and other measures of socioeconomic status and risk of incident Alzheimer disease in a defined population of older persons. Arch Neurol 1997 Nov; 54: 1399–405.Google Scholar
  19. 19.
    Andersen K, Nielsen H, Lolk A, et al. Incidence of very mild to severe dementia and Alzheimer’s disease in Denmark: the Odense study. Neurology 1999 Jan 1; 52: 85–90.PubMedCrossRefGoogle Scholar
  20. 20.
    Chandra V, Ganguli M, Pandav R, et al. Prevalence of Alzheimer’s disease and other dementias in rural India: the Indo-US study. Neurology 1998 Oct; 51: 1000–8.Google Scholar
  21. 21.
    Chiu HFK, Lam LCW, Chi I, et al. Prevalence of dementia in Chinese elderly in Hong Kong. Neurology 1998 Apr; 50: 1002–9.Google Scholar
  22. 22.
    The Canadian Study of Health and aging. Canadian study of health and aging: study methods and prevalence of dementia. Can Med Assoc J 1994; 150 (6): 899–913.Google Scholar
  23. 23.
    Meek PD, McKeithan EK, Schumock GT. Economic considerations in Alzheimer’s disease. Pharmacotherapy 1998 Mar-1998 30; 18 (Part 2): 68–73.PubMedGoogle Scholar
  24. 24.
    Trabucchi M. An economic perspective on Alzheimer’s disease. J Geriatr Psychiatry Neurol 1999; 12 (No. 1): 29–38.PubMedCrossRefGoogle Scholar
  25. 25.
    Max W. The economic impact of Alzheimer’s disease. Neurology 1993 Aug; 43 (Suppl. 4): 6–10.Google Scholar
  26. 26.
    Ernst RL, Hay JW. The US economic and social costs of Alzheimers disease revisited. Am J Public Health 1994; 84 (8): 1261–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Rice DP, Fillit HM, Max W, et al. Prevalence, costs, and treatment of Alzheimer’s disease and related dementia: a managed care perspective. Am J Manag Care 2001 Aug; 7 (8): 809–18.PubMedGoogle Scholar
  28. 28.
    O’Brien BJ, Goeree R, Hux M, et al. Economic evaluation of donepezil for the treatment of Alzheimer’s disease in Canada. J Am Geriatr Soc 1999 May; 47: 570–8.Google Scholar
  29. 29.
    Williams JK, Trubatch AD. Nursing home care for the patient with Alzheimers disease. Neurology 1993; 43 (Suppl. 4): 20–4.Google Scholar
  30. 30.
    Welch HG, Walsh JS, Larson EB. The cost of institutional care in Alzheimer’s disease: nursing home and hospital use in a prospective cohort. J Am Geriatr Soc 1992 Mar; 40: 221–4.Google Scholar
  31. 31.
    Rice D, Fox P, Max W, et al. The Economic Burden of Alzheimer’s Disease Care. Health Aff (Millwood) 1993 Summer: 164–76.Google Scholar
  32. 32.
    Rice DP, Fox P, Hauck W, et al. The burden of caring for Alzheimers disease patients. Proceedings of the 1991 Public Health Conference on Records and Statistics. 1991 US Department of Health and Human Services: 119–24.Google Scholar
  33. 33.
    Doody RS, Stevens JC, Beck C, et al. Practice parameter: Management of dementia (an evidence-based review). Neurology 2001; 56: 1154–66.PubMedCrossRefGoogle Scholar
  34. 34.
    Fillit H, Cummings J. Practice guidelines for the diagnosis and treatment of Alzheimer’s disease in a managed care setting: Part II—Pharmacologic therapy. Alzheimer’s Disease (AD) Managed Care Advisory Council. Manag Care Interface 2000 Jan; 13 (1): 51–6.PubMedGoogle Scholar
  35. 35.
    Donepezil for the management of patients with Alzheimer’s disease: a good choice from among the cholinesterase inhibitors. Drug Ther Perspect 2001 Jun 4; 17 (11): 1–6.Google Scholar
  36. 36.
    ARICEPT® (donepezil hydrochloride tablets). US Package Insert. 2000 Dec; Eisai Inc, Teaneck, NJ..Google Scholar
  37. 37.
    REMINYL® (galantamine hydrobromide) tablets. US Package Insert. 2001 Feb; Janssen Pharmaceutica Products, Titusville, NJ..Google Scholar
  38. 38.
    EXELON® (rivastigmine tartrate) capsules. US Package Insert. 2001 Jan; Novartis Pharmaceuticals Corporation LP, East Hanover, NJ..Google Scholar
  39. 39.
    Gauthier S. Acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease. Expert Opin Invest Drugs 1999 Oct; 8: 1511–20.Google Scholar
  40. 40.
    Schachter AS, Davis KL. Guidelines for the appropriate use of cholinesterase inhibitors in patients with Alzheimer’s disease. CNS Drugs 1999 Apr; 11: 281–8.Google Scholar
  41. 41.
    Grutzendler J, Morris JC. Cholinesterase inhibitors for Alzheimer’s disease. Drugs 2001; 61 (No. 1): 41–52.PubMedCrossRefGoogle Scholar
  42. 42.
    McGleenon BM, Dynan KB, Passmore AP Acetylcholinesterase inhibitors in Alzheimer’s disease. Br J Clin Pharmacol 1999 Oct; 48: 471–80.PubMedCrossRefGoogle Scholar
  43. 43.
    Lamb HM, Goa KL. Rivastigmine: A pharmacoeconomic review of its use in Alzheimer’s disease. Pharmaceconomics 2001; 19 (3): 303–18.CrossRefGoogle Scholar
  44. 44.
    Galantamine for Alzheimer’s disease. The Medical Letter 2001 Jun 25; 43 (1107): 53–4.Google Scholar
  45. 45.
    Scott LJ, Goa KL. Galantamine: A review of its use in Alzheimer’s disease. Drugs 2001; 60 (5): 1095–122.CrossRefGoogle Scholar
  46. 46.
    Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med 1997; 336: 1216–22.PubMedCrossRefGoogle Scholar
  47. 47.
    Shinotoh H, Aotsuka A, Fukushi K, et al. Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET. Neurology 2001 Feb 13; 56 (3): 408–10.PubMedCrossRefGoogle Scholar
  48. 48.
    Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 1996; 7: 293–303.Google Scholar
  49. 49.
    Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 1998; 50: 136–45.PubMedCrossRefGoogle Scholar
  50. 50.
    Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998 May 11; 158 (9): 1021–31.PubMedCrossRefGoogle Scholar
  51. 51.
    Greenberg SM, Tennis MK, Brown LB, et al. Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol 2000 Jan; 57 (1): 94–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer’s disease — results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237–44.PubMedCrossRefGoogle Scholar
  53. 53.
    Homma A, Takeda M, Imai Y, et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer’s disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord 2000 Nov-2000 31; 11 (6): 299–313.PubMedCrossRefGoogle Scholar
  54. 54.
    Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001 Aug 14; 57 (3): 489–95.PubMedCrossRefGoogle Scholar
  55. 55.
    Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001 Aug 14; 57 (3): 481–8.PubMedCrossRefGoogle Scholar
  56. 56.
    McLendon BM, Doraiswamy PM. Defining meaningful change in Alzheimer’s disease trials: the donepezil experience. J Geriatr Psychiatry Neurol 1999 Spring; 12 (1): 39–48.PubMedCrossRefGoogle Scholar
  57. 57.
    Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001 Mar; 58 (3): 427–33.PubMedCrossRefGoogle Scholar
  58. 58.
    Rogers SL, Doody RS, Pratt RD, et al. Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000 May; 10 (3): 195–203.PubMedCrossRefGoogle Scholar
  59. 59.
    Bråne G, Gottfries CG, Winblad B, et al. The Gottfries-Bråne-Steen scale: validity, reliability and application in antidementia drug trials. Dement Geriatr Cogn Disord 2001; 12: 1–14.PubMedCrossRefGoogle Scholar
  60. 60.
    Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001 Aug 28; 57 (4): 613–20.PubMedCrossRefGoogle Scholar
  61. 61.
    Davis KL, Mohs RC, Marin D, et al. Cholinergic markers in elderly patients with early signs of Alzheimer’s disease. JAMA 1999; 281: 1401–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Wilkinson DG, Passmore P, Smith R, et al. Comparison of the tolerability, ease of use, and efficacy of donepezil and rivastigmine in Alzheimer’s disease patients: a 12-week multinational study [abstract no. S54.003]. Neurology 2001; 56 (Suppl. 3): 456–7.Google Scholar
  63. 63.
    Shintani EY, Uchida KM. Donepezil: an anticholinesterase inhibitor for Alzheimer’s disease. Am J Health Syst Pharm 1997 Dec 15; 54: 2805–10.PubMedGoogle Scholar
  64. 64.
    Dunn NR, Pearce GL, Shakir SA. Adverse effects associated with the use of donepezil in general practice in England. J Psychopharmacol 2000; 14 (4): 406–8.PubMedCrossRefGoogle Scholar
  65. 65.
    McRae T, Orazem J. A large, community-based, open-label trial of donepezil in the treatment of Alzheimer’s disease (AD) [abstract]. J Am Geriatr Soc 1999; 47: S63.Google Scholar
  66. 66.
    Alom J, Leblhuber F, Cras P, et al. Donepezil for the treatment of Alzheimer’s disease: a multinational clinical experience study [abstract]. Int Psychogeriatr 2001; 13 (Suppl 2): 245S.Google Scholar
  67. 67.
    McRae T, Knopman D, Duttagupta S, et al. Donepezil delays time to nursing home placement in patients with Alzheimer’s disease [abstract]. XVII World Congress of Neurology, London 17–22 June 2001.Google Scholar
  68. 68.
    Small GW, Donohue JA, Brooks RL. An economic evaluation of donepezil in the treatment of Alzheimer’s disease. Clin Ther 1998 Jul-1998 31; 20: 838–50.PubMedCrossRefGoogle Scholar
  69. 69.
    Fillit H, Gutterman EM, Lewis B. Donepezil use in managed Medicare: effect on health care costs and utilization. Clin Ther 1999 Dec; 21 (12): 2173–85.PubMedCrossRefGoogle Scholar
  70. 70.
    Stewart A, Phillips R, Dempsey G. Pharmacotherapy for people with Alzheimer’s disease: a Markov-cycle evaluation of five years’ therapy using donepezil. Int J Geriatr Psychiatry 1998 Jul; 13 (7): 445–53.PubMedCrossRefGoogle Scholar
  71. 71.
    Jonsson L, Lindgren P, Wimo A, et al. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer’s disease: a Markov model. Clin Ther 1999 Jul; 21: 1230–40.Google Scholar
  72. 72.
    Neumann PJ, Kuntz KM, Hermann RC, et al. The cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease. Med Decis Making 1997 Oct 31; 17:532.Google Scholar
  73. 73.
    Wimo A, Winblad B, Mastey V, et al. An economc evaluation of donepezil in mild to moderate Alzheimer’s disease patients: results of a one-year, double-blind, randomized trial. APA 2000 N 2000 May 13: 129.Google Scholar

Copyright information

© Adis International Limiteds 2002

Authors and Affiliations

  1. 1.Adis International LimitedMairangi Bay, Auckland 10New Zealand

Personalised recommendations